Writing in Acta Pharmaceutica Sinica B, researchers explained how this could seriously affect intestinal function, increasing obstruction risk: 24 "Because GLP-1RAs could cause continuous increases in the intestinal length and villus height, the small intestine may become as inelastic and fibrotic as a loose spring, leading to long-term upper intestinal obstruction ..." To date, clinical trials havent revealed such changes in the human gut, likely because its difficult to measure small intestine length
Oxidative stress accelerates kidney disease by promoting complications such as inflammation, hypertension, anemia, and atherosclerosis ultimately accelerating the progression to ESRD [11, 12]
Keep it in the box: Light can degrade the medication
This precision approach reduces adverse event risk while maximizing therapeutic benefit, ensuring that depression concerns don't overshadow the substantial health gains many achieve through GLP-1 therapy